TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04213898
Drug: SHR-1210+Albumin-bound paclitaxel + epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant therapy：SHR-1210, 200mg,iv, q3w, for 6 cycles; Albumin-bound paclitaxel: 125 mg/m2, iv, d1, d8, and d15, 21 days as a cycle, for 6 cycles; Epirubicin: 75mg / m2, iv, d1, 21 days as a cycle, for 6 cycles; The surgery was performed 3-4 weeks after the completion of neoadjuvant chemotherapy.
Study: NCT01589432
Drug: ABT-639
Normalized name: ABT-639
DrugBank: ABT-639 (DB15055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: two 50 mg oral capsules
Study: NCT01589432
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3mg/kg infusion over 30 minutes
Study: NCT00095758
Drug: Antidepressant + Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
Study: NCT03945981
Drug: Dolutegravir + Lamivudine FDC
Normalized name: DOLUTEGRAVIR/LAMIVUDINE
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dolutegravir + Lamivudine FDC is available as white oval film-coated tablets which are packed in high density polyethylene (HDPE) bottles with induction seals and child-resistant closures. Each 60 milliliter (mL) bottle contains 30 tablets
Study: NCT00758628
Drug: Blink
Normalized name: Blink Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blink BID for 3 months
Study: NCT01660412
Drug: ph Altered first
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the first injection, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to \~7.40. For the second injection, the standard of care will be given, and randomly after that either standard of care, or pH altered will be given.
Study: NCT00665600
Drug: Levalbuterol HCl
Normalized name: levalbuterol HCl
DrugBank: Levosalbutamol (DB13139)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levalbuterol 0.63 TID
Study: NCT00665600
Drug: Levalbuterol HCl
Normalized name: levalbuterol HCl
DrugBank: Levosalbutamol (DB13139)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levabuterol 1.25 mg TID
Study: NCT00665600
Drug: Albuterol Sulfate
Normalized name: Albuterol Sulfate
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic albuterol 2.5 mg TID
Study: NCT03118128
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 850 mg PO three times a day plus prednisone in one 7-days cycle as pre-treatment and during the 28 days induction remission treatment, consolidation therapy and maintenance
Study: NCT00590954
Drug: Perifosine
Normalized name: Perifosine
DrugBank: Perifosine (DB06641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing will be continuous, and for the purpose of this trial a cycle will be defined as 28 days. Perifosine will be given as a 600 mg loading dose on day 1. The loading dose will be divided into 4 equal doses of 150 mg each. The first 3 doses should be given with food in the adult day hospital to allow intravenous antiemetic prophylaxis, and 4th dose at bedtime at home. The interval between doses of perifosine should be no less than 4 hours. On day 2, patients will start the maintenance dose of 100 mg daily at bedtime at home.~In addition to baseline serum, all patients will have weekly serum drawn during weeks 2-4.
Study: NCT03551210
Drug: Nemonoxacin
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion, 500 mg (250 ml)
Study: NCT03551210
Drug: Nemonoxacin
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, 250 mg
Study: NCT03551210
Drug: Tavanic
Normalized name: Cassia javanica whole extract
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution for infusion, 500 mg (100 ml)
Study: NCT03551210
Drug: Tavanic
Normalized name: Cassia javanica whole extract
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Film coated tablets (each tablet is placed into a capsule shell (overencapsulated) for blinding purposes), 250 mg
Study: NCT00001249
Drug: Yttrium-90 radiolabeled anti-Tac antibody
Normalized name: yttrium
DrugBank: Yttrium Y-90 (DB13076)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01331148
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10,000 IU/caplet, patients receiving 240,000 IU to 600,000 IU cumulative Vitamin D dose based on weight.
Study: NCT03228134
Drug: Yang He Ping Chuan Granule
Normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine
Study: NCT00003217
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003217
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003217
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002510
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002510
Drug: mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01527552
Drug: biphasic insulin aspart 50
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
Study: NCT02398552
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: altenative schedules of sunitinib as first line therapy in metastatic renal cell carcinoma patients.
Study: NCT04380857
Drug: Dexamethasone ophthalmic insert 0.4 mg
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intracanalicular dexamethasone insert
Study: NCT04132557
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three United States (US) health care databases and one US electronic health record database.
Study: NCT04132557
Drug: Lisdexamfetamine
Normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three US health care databases and one US electronic health record database.
Study: NCT04132557
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
Study: NCT04132557
Drug: Amphetamine
Normalized name: Amphetamine
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
Study: NCT04132557
Drug: Dextroamphetamine
Normalized name: Dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
Study: NCT00514267
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT00514267
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT00973791
Drug: Six percent hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch (6%) was given before or after spinal anesthesia in cesarean section
Study: NCT04734405
Drug: Fluconazole 150 mg
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole capsule
Study: NCT00222469
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10mg/kg IV on Day 1 Q 2 weeks
Study: NCT00222469
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 as fixed-rate infusion at 10mg/m2/min on Day 1 and Q 2 weeks.
Study: NCT00222469
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100mg/m2 on Day 2 and Q 2 weeks.
Study: NCT01888497
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg, oral, prior to bedtime on the night before performance testing
Study: NCT01888497
Drug: Diphenhydramine citrate
Normalized name: Diphenhydramine Citrate
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 76 mg, oral, prior to bedtime on the night before performance testing
Study: NCT01888497
Drug: Triazolam
Normalized name: Triazolam
DrugBank: Triazolam (DB00897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg, oral, prior to bedtime on the night before performance testing
Study: NCT03240575
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Dose Combination
Study: NCT03240575
Drug: Olodaterol
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed Dose Combination
Study: NCT03240575
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fixed Dose Combination
Study: NCT03240575
Drug: Salmeterol
Normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fixed Dose Combination
Study: NCT04561076
Drug: HLX70
Normalized name: HLX70
DrugBank: HLX70 (DB16509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose, intravenous infusion
Study: NCT04223076
Drug: Chlorhexidine 0.2%, Corsodyl
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of Corsodyl and Curasept
Study: NCT04223076
Drug: Chlorhexidine 0.2%, Curasept
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine 0.2% mouthwash with an Anti Discoloring System (ADS)
Study: NCT03568942
Drug: Gepotidacin
Normalized name: gepotidacin
DrugBank: Gepotidacin (DB12134)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepotidacin tablets will be available at a dose strength of 750 mg. Tablets will be administered BID with water after consumption of food.
Study: NCT00983554
Drug: Anastrazole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arimidex 1mg daily
Study: NCT00983554
Drug: Dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Avodart 2.5mg daily
Study: NCT00983554
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyline 300 µg/kg subcutaneous injections every 2 weeks
Study: NCT01076985
Drug: Lopinavir/ritonavir (Kaletra)
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lopinavir/ritonavir (LPV/r) evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
Study: NCT01422499
Drug: zolinza/vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: orally once per day (suspension of 50mg/ml or capsules of 100 mg vorinostat); starting dose will be 180 mg/m²/d; escalated with increments of 50 mg/m²/d every two weeks until dose limiting toxicity (grade 3 or 4 toxicity according to CTC) occurs or up to a maximum dose of 580 mg/m²/d; This dose will then be applied for 3 months. Patients without progression at first response evaluation will continue treatment for a maximum of 9 months.
Study: NCT00202904
Drug: ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ezetimibe 10 mg tablets, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
Study: NCT00733720
Drug: Suboxone
Normalized name: Suboxone
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4/1mg, 8/2mg 16/4mg
Study: NCT01674686
Drug: Sarpogrelate
Normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate 100mg twice a day
Study: NCT01674686
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 80mg daily
Study: NCT03391973
Drug: Pembrolizumab Injection
Normalized name: pembrolizumab Injection
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
Study: NCT03692546
Drug: Liposomal bupivacaine (LB)
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Addition of LB solution to soft tissue surgical field block to a standard interscalene block procedure
Study: NCT03607916
Drug: Hyperbaric prilocaine 2%
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varying dose according to sensitive response of previous subjects. All study doses of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
Study: NCT03607916
Drug: Hyperbaric prilocaine 2%
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose of 60 mg of Hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
Study: NCT03607916
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100µg morphine
Study: NCT02881294
Drug: SUVN-G3031
Normalized name: SUVN-G3031
DrugBank: SUVN-G3031 (DB14835)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00864162
Drug: Ramipril10 mg Capsules, single dose
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A: Experimental Subjects received Purepac formulated products under fed conditions
Study: NCT02677090
Drug: Placebo (including Maltodextrin)
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01218516
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered intravenously to achieve area under the serum concentration-time curve of 5 to 6 mg/mL\^min \[AUC5-6\].
Study: NCT01218516
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m\^2 will be administered intravenously.
Study: NCT01218516
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed 500 mg/m\^2 will be administered intravenously.
Study: NCT01218516
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m\^2 will be administered intravenously.
Study: NCT03111420
Drug: P2Y12 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of P2Y12 inhibitor antiplatelet therapy
Study: NCT02643251
Drug: Clonidine Hydrochloride Topical Gel, 0.1%
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine Gel is supplied as an aqueous gel formulation for topical use.
Study: NCT02643251
Drug: Clonidine Hydrochloride Gel Comparator
Normalized name: Clonidine Hydrochloride
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine Gel Comparator is supplied as an aqueous gel formulation for topical use.
Study: NCT02129075
Drug: Poly ICLC
Normalized name: Poly iclc
DrugBank: Hiltonol (DB17293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given SC
Study: NCT04933591
Drug: Diosmin / Hesperidin
Normalized name: diosmin / hesperidin
DrugBank: Hesperidin (DB04703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venoactive drugs are used for patients with varicose veins as a tool for alleviating symptoms
Study: NCT04657536
Drug: promestriene vaginal soft capsules
Normalized name: promestriene
DrugBank: Promestriene (DB12487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promestriene vaginal soft capsules（Zhejiang Anbao Pharmaceutical Co. LTD）will be used 10mg once a day for continuous 20 days.
Study: NCT01944059
Drug: Theramine (medical food/old drug)
Normalized name: phentermine hydrochloride Oral Tablet [Teramine]
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theramine® is a prescription medical food that is composed of variety of amino acids and/or their precursors.
Study: NCT00028756
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00028756
Drug: vinblastine sulfate
Normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00028756
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02731742
Drug: SD-101
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD-101 administered as an intratumoral (IT) injection
Study: NCT03613207
Drug: Lidocaine and prilocaine cream
Normalized name: Lidocaine and Prilocaine Cream
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US) will be applied to 6 test sites per subject
Study: NCT00049062
Drug: anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00049062
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004923
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004923
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01034410
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine 2g/m2 bid Days 4-7
Study: NCT04400721
Drug: Erector spinae plane block with ropivacaine 3.75mg/ml
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single shot erector spinae block
Study: NCT01304485
Drug: Sodium Acetate C11
Normalized name: Choline C11
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET Imaging with Sodium Acetate C11
Study: NCT00808288
Drug: PF-00610355
Normalized name: PF-00610355
DrugBank: PF-00610355 (DB11871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, inhaled, dry powder, 600ug, OD
Study: NCT00808288
Drug: PF - 00610355
Normalized name: PF-00610355
DrugBank: PF-00610355 (DB11871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, inhaled, dry powder, 300ug, OD
Study: NCT00808288
Drug: PF- 00610355
Normalized name: PF-00610355
DrugBank: PF-00610355 (DB11871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, inhaled, dry powder, 100ug, OD
Study: NCT00808288
Drug: Salmeterol
Normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: salmeterol, 50ug, BID
Study: NCT02191189
Drug: Nevirapine suspension, into Enterion™ capsule
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02191189
Drug: Nevirapine suspension
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00614016
Drug: Sodium ST20
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single administration of oral dosage form
Study: NCT00193401
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02096458
Drug: Dexlansoprazole
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole delayed-release orally disintegrating tablets
Study: NCT02105077
Drug: Anesthesia with inhalative application of xenon gas
Normalized name: xenon (133Xe) gas
DrugBank: Xenon (DB13453)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05429450
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three periocular injections of triamcinolone acetonide at week 0, week 3 and week 6.
Study: NCT01010282
Drug: Glycerin and Polysorbate 80 based artificial tear
Normalized name: glycerin / polysorbate 80
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-2 drops in each eye, as needed, but at least twice daily
Study: NCT01010282
Drug: Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-2 drops in each eye, as needed, but at least twice daily
Study: NCT01010282
Drug: Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-2 drops in each eye, as needed, but at least twice daily
Study: NCT00080847
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV